Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.
暂无分享，去创建一个
Edward S. Kim | N. Reinmuth | M. Ahn | S. Peters | N. Rizvi | B. Cho | S. Antonia | K. Nakagawa | R. Raja | K. Lee | Jill Walker | V. Moiseyenko | D. Vicente | A. Smolin | U. Scheuring | S. Goldberg | M. C. Dols | A. Luft | F. Liu | M. M. Heuvel